Search

Displaying results 1381 - 1390 of 10000 in total
  1. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    It has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230123] The increased potency makes melphalan flufenamide a treatment option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of therapy already.

  2. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863] … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer

  3. Drug

    Bordetella pertussis pertactin antigen

    go.drugbank.com/drugs/DB10789
    ApprovedInvestigational

    Bordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis [A31248].

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Covaxis Injektionssuspension in einer Fertigspritze
  4. Drug

    Hexylresorcinol

    go.drugbank.com/drugs/DB11254
    Approved

    It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain relief and first aid antiseptic. … The compound may also be used commonly in various commercial cosmetic anti-aging creams while ongoing studies research the possibility of using hexylresorcinol as an anti-cancer therapy - indications all

  5. Drug

    Lactic acid

    go.drugbank.com/drugs/DB04398
    ApprovedInvestigationalVet approved

    A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. … Lactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]

    Mixtures: Dextrose in Lactated Ringers, D5-LRI (5% DEXTROSE IN LOCTATED RINGER'S INJ.)
  6. Drug

    Pertussis vaccine

    go.drugbank.com/drugs/DB15274
    ApprovedInvestigational

    Pertussis vaccine is under investigation in clinical trial NCT01698346 (Pertussis (Tdap) Vaccination in Pregnancy).

    Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, dTaP Booster Injektionssuspension in einer Fertigspritze
  7. Drug

    Ingenol mebutate

    go.drugbank.com/drugs/DB05013
    ApprovedWithdrawn

    PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations. … Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.

  8. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus. … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart

  9. Drug

    Nebivolol

    go.drugbank.com/drugs/DB04861
    ApprovedInvestigational

    [A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics. … [A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].

    Products: CORETEL-N
  10. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line

    Products: I-HEP CLASTAVIR 30, I-HEP CLASTAVIR 60